• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Naturillusionen erobern die Schweiz

, Medizintechnik, Sky Factory Deutschland OHG

Graue Flure, stählerne Bettgestelle und kaltes Licht aus Neonröhren: medizinische Einrichtungen sorgen durch ihre alltagstauglichen Räumlichkeiten...

BIOTRONIK Announces Completion of Enrollment in SFA Arm of the BIOFLEX-I Study

, Medizintechnik, BIOTRONIK

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, today announced the completion of patient enrollment in the superficial...

B. Braun unterstützt Tanzkurse für Rollstuhlfahrer

, Medizintechnik, B. Braun Melsungen AG

Die Kultur- und Sportgruppe Rhein-Neckar bietet in Zusammenarbeit mit B. Braun Melsungen an vier Abenden Tanzworkshops für Rollstuhlfahrer an....

Disclaimer